Drug Trial Radar · NCT07622810
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
352
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Carnot LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity. It will also evaluate the effects of treatment on metabolic parameters, cardiovascular risk factors, and quality of life. The main questions it aims to answer are: Does Bofanglutide (GZR18) reduce body weight after 36 weeks of treatment compared with Semaglutide? What effects does Bofanglutide (GZR18) have on metabolic parameters, cardiovascular risk factors, and quality of life? How safe and well tolerated is treatment with Bofanglutide (GZR18)? Researchers will compare Bofanglutide (GZR18) with Semaglutide, an active comparator, to evaluate efficacy and safety in adults with overweight or obesity. Participants will: Receive Bofanglutide (GZR18) every 2 weeks or Semaglutide once weekly by subcutaneous injection Follow standardized recommendations for diet and physical activity throughout the study Attend scheduled clinic visits for efficacy and safety assessments Participate in treatment and follow-up for up to 40 weeks, including screening, treatment, and safety follow-up periods
Conditions
- Obesity & Overweight
Interventions
BofanglutidaDrug
Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks. Participants will receive progressive dose titration starting at 3 mg up to a target dose of 48 mg according to the study protocol during the 36-week treatment period.
SemaglutideDrug
Semaglutide is a GLP-1 receptor agonist administered by weekly subcutaneous injection with progressive dose titration from 0.25 mg to 1 mg according to the study protocol during the 36-week treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Body Weight From Baseline to Week 36Time frame: Baseline to Week 36
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Instituto Nacional de Cardiología "Ignacio Chávez"
Mexico City, Mexico
Centro de Investigación Clínica y Medicina Traslacional (CIMeT)
Guadalajara, Jalisco, Mexico
CICMEX Centro de Investigación Clínica de México S de RL de CV.
Morelia, Michoacán, Mexico
SMIQ, S. de R.L. de C.V.
Querétaro City, Querétaro, Mexico
Investigación Médica Sonora S.C.
Hermosillo, Sonora, Mexico
Centro de Estudios de lnvestigación Metabólicos y Cardiovasculares, S.C.
Ciudad Madero, Tamaulipas, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.